Pfizer/BioNTech say 3 COVID shots elicit good response in children under 5

13 Sept 11:47 Key points summarised by AI

Pfizer and BioNTech announced their COVID-19 vaccine, given in three doses, generated a strong immune response and was safe for children aged 6 months to under 5 years in clinical trials.
The drugmakers intend to promptly seek authorization from global regulators, including the U.S. FDA, for this age group, which currently lacks an approved COVID-19 vaccine.
The trial involved 1,678 children receiving three smaller 3-microgram doses, demonstrating an immune response comparable to that seen in 16-25 year olds who received two standard 30-microgram doses.
An early analysis indicated an 80.3% vaccine efficacy against symptomatic COVID-19 cases in the under-5 age group during the Omicron variant's dominance, with final efficacy data pending.

Thailand News in Brief